You are here: Industry Insights > BYDUREON BCise

News List

FDA Approves Pediatric Type 2 Diabetes Treatment americanpharmaceuticalreview
July 26, 2021
The U.S. FDA approved Bydureon and Bydureon BCise (exenatide extended-release) injection to be used in addition to diet and exercise to improve glycemic control (blood sugar levels) in pediatric patients 10 years or older with type 2 diabetes.
EU approves AZ’ Bydureon BCise device pharmatimes
September 14, 2018
AstraZeneca says the European Commission has approved a new formulation of its once-weekly diabetes drug Bydureon.
European Commission Approves Bydureon BCise Device for Patients with Type-2 Diabetes americanpharmaceuticalreview
August 31, 2018
AstraZeneca announced the European Commission (EC) has approved Bydureon BCise (exenatide 2mg prolonged-release suspension for injection in pre-filled pen) as a new formulation within the marketing authorization for Bydureon (exenatide extended release) f
AstraZeneca's BYDUREON BCise Injectable Medicine Now Available in the U.S. for Patients With Type-2 biospace
January 11, 2018
AstraZeneca today announced that BYDUREON® BCise™ (exenatide extended-release) injectable suspension 2mg is now available in pharmacies across the United States.